{"slug":"retatrutide-semaglutide","verification":{"valid":true,"entries":2,"head":"682429816197f66735d62a388d921d8ca9cfb893230e82b7ac421dbd993a8860"},"energy":{"passes":2,"tokens_in":19390,"tokens_out":3187,"tokens_total":22577,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"682429816197f66735d62a388d921d8ca9cfb893230e82b7ac421dbd993a8860"},"provenance":[{"ts":"2026-06-30T00:52:06.017Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Retatrutide for Semaglutide\nSlug: retatrutide-semaglutide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"retatrutide\",\"name\":\"Retatrutide\"},{\"id\":\"semaglutide\",\"name\":\"Semaglutide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"retatrutide\",\"name\":\"Retatrutide\",\"section_title\":\"Why Retatrutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\",\"**What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\",\"**Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — ","response":"{\n  \"slug\": \"retatrutide-semaglutide\",\n  \"title\": \"Retatrutide and Semaglutide: Evidence on Weight Loss for Reducing Mechanical Load\",\n  \"body\": \"## What's breaking down\\n\\nExcess body weight increases compressive forces on weight-bearing tissues. Each extra pound of body weight adds roughly four pounds of compressive load to the lumbar spine during standing or walking. The same multiplier applies to hips, knees, and plantar fascia. Over time this sustained overload can outpace the tissue's natural repair capacity. Metabolic stress from excess adipose tissue may further impair repair signaling. The result is a cycle where degeneration proceeds faster than regeneration in these structures.\\n\\nBoth retatrutide and semaglutide are studied primarily for their effects on body weight. Weight reduction lowers the absolute mechanical load placed on these tissues. This addresses one layer of the problem without directly acting on disc cells or cartilage matrix.\\n\\n## Why Retatrutide might help you\\n\\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\nA phase 2 human trial measured body-weight change at 48 weeks. Participants receiving the highest dose reached a mean reduction of 24.2 percent versus 2.1 percent on placebo (human data). Later phase 3 data reported 28.3 percent mean loss at 80 weeks on 12 mg, with further extension to 30.3 percent at 104 weeks in a subset (human data). These reductions translate directly into lower daily compressive forces on the spine and joints.\\n\\n## Why Semaglutide might help you\\n\\n1. What keeps failing: Weight-related joint and disc overload; metabolic stress on re","tokens_in":19390,"tokens_out":3187,"cost":0,"prev":"genesis","hash":"a145a72e97066f54f84fe98fc465824e901b964cfa06c88db6f0bf87c8d199c2"},{"ts":"2026-07-17T02:41:20.958Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-semaglutide","response":"25 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a145a72e97066f54f84fe98fc465824e901b964cfa06c88db6f0bf87c8d199c2","hash":"682429816197f66735d62a388d921d8ca9cfb893230e82b7ac421dbd993a8860"}]}